Coherus BioSciences

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Coherus BioSciences targets profitability in 2024 with strong product focus

Coherus BioSciences is strategically positioned to achieve profitability in 2024 through revenue growth and cost control. The company's strong product portfolio and focus on user-friendly solutions provide a competitive edge. Challenges include competition and regulatory approvals, while opportunities exist in expanding product approvals and optimizing expenses.

Coherus BioSciences reports robust Q1 results and eyes market expansion

Coherus BioSciences showcased strong financial performance, product advancements, and strategic initiatives during their Q1 2023 Earnings Call, positioning them for future growth.
While facing challenges such as potential competition and pricing uncertainties, the company's strengths in product diversity, patient engagement, and commercial readiness offer a solid foundation for success.
By capitalizing on opportunities like FDA approvals, therapy combinations, and market share goals, Coherus can navigate challenges and drive innovation in the biopharmaceutical market.

Coherus BioSciences posts robust Q2 earnings, eyes market expansion

Coherus BioSciences reported strong Q2 2023 performance with net product revenues of $58.5 million.
The company aims to achieve cash flow positivity in 2024 through expense management and revenue growth.
Focus on offering low-cost alternatives like CIMERLI and expanding market share for key products.
Plans to leverage the successful launches of UDENYCA and Toripalimab for future growth opportunities.

Coherus BioSciences reports strong Q3 revenue growth and profitability focus

Coherus BioSciences showed strong revenue growth and expense management focus for profitability.
Key products like CIMERLI and UDENYCA drove revenue growth in Q3 2023.
Adjusting R&D expenses to align with revenue and focusing on profitability until mid-2024.
Analysts raised questions on pricing dynamics, profitability goals, and pipeline development plans.

Coherus BioSciences reports strong Q4 results and focuses on growth

Coherus BioSciences showcased strong Q4 results, focusing on efficiency and growth in 2024.
The company achieved FDA approvals for key products, with UDENYCA sales showing growth and LOQTORZI gaining traction.
Financials highlighted cost reductions and pipeline progress, with a cautious approach to revenue projections.
Emphasis on controlling expenses, reducing debt, and driving revenues higher while investing in key products.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Bluerock Residential Growth REIT

Huntington Ingalls Industries

Installed Building Products

Wall Street continues to build on a steep rebound in the previous session after lockdown strategy stabilized coronavirus outbreak in the United States and abroad.

Signs of Coronavirus Slowdown Pep Up Wall Street: 5 Winners

Coherus BioSciences (CHRS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is Coherus BioSciences (CHRS) Stock a Solid Choice Right Now?

REDWOOD CITY, Calif., March  20, 2020  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective March 19, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 57,500 shares of the common stock of the Company to three newly hired non-officer employees, with a per share exercise price of $12.86, the closing trading price on the grant date.

Coherus BioSciences Announces - New Employment Inducement Grants

Coherus BioSciences: Current Weakness Represents A Buying Opportunity

Century Communities

LGI Homes

QIAGEN

Regeneron Pharmaceuticals

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

5 Stocks Trading Near 52-Week  High That Can Scale Higher.

Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q4 2019 Results - Earnings Call Transcript

We expect Coherus BioSciences (CHRS) to provide updates on its pipeline when it releases fourth-quarter 2019 results.

Coherus (CHRS) to Report Q4 Earnings: What's in the Cards?

REDWOOD CITY, Calif., Feb.  20, 2020  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 18, 2020, the compensation committee of the Company’s board of directors granted options to purchase 135,000 shares of the common stock of the Company to four newly hired non-officer employees, with a per share exercise price of $22.16, the closing trading price on the grant date.

Coherus BioSciences  Announces New Employment Inducement Grants

Is  (CHRS) Outperforming Other Medical Stocks This Year?

Has Coherus BioSciences (CHRS) Outpaced Other Medical Stocks This Year?

Coherus BioSciences (CHRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Coherus BioSciences (CHRS) Upgraded to Strong Buy: Here's Why

Coherus BioSciences Offers Compelling Long-Term Gain Opportunities With Low Risk

Agreement Includes an Option for Rituxan® Biosimilar Agreement Includes an Option for Rituxan® Biosimilar

Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States

Is Coherus BioSciences (CHRS) Stock Outpacing Its Medical Peers This Year?

MeiraGTx Holdings plc

Moderna

uniQure

XOMA

The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.

5 Biotech Stocks Set for Continued Rally in 2020

Personalis Inc

These small-cap biopharma stocks offer intriguing potential in 2020 and beyond.

2 Top Small-Cap Stocks to Buy in December

Amkor Technology

Copart

Hibbett Sports

Top Ranked Momentum Stocks to Buy for November 26th

The company's Neulasta biosimilar has generated $232 million in revenue in the first nine months of 2019, but its growth rate will slow soon.

If Biosimilars Are Struggling, Someone Forgot to Tell Coherus BioSciences

ACADIA Pharma

Celgene

Incyte

The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

4 Biotech Stocks That Could Keep Beating Wall Street

REDWOOD CITY, Calif., Nov.  08, 2019  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective November 7, 2019, the compensation committee of the Company’s board of directors granted options to purchase 77,000 shares of the common stock of the Company to eight newly hired non-officer employees, with a per share exercise price of $19.00, the closing trading price on the grant date.

Coherus BioSciences Announces  New Employment Inducement Grants

Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q3 2019 Results - Earnings Call Transcript

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 75.00% and 19.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Coherus BioSciences (CHRS) Q3 Earnings and Revenues Surpass Estimates

Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q2 2019 Results - Earnings Call Transcript

Deutsche Bank

Intra-Cellular Therapies

Why Deutsche Bank, Intra-Cellular Therapies, and Coherus BioSciences Slumped Today

The business reported an upbeat update, but something got lost in translation on Wall Street.

Here's Why Coherus BioSciences Is Falling Today

Coherus BioSciences (NASDAQ: CHRS) announced that UDENYCA preliminary unaudited net sales for the second quarter expected in the range of $79 million-$84 million.

News for Coherus BioSciences Stock (CHRS)